Recent Updates
Recently added Catalysts
FLGT Negative Sentiment

Fulgent Reports Second Quarter 2026 Financial Results

Thursday, July 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Fulgent Genetics, Inc. reported its financial results for the second quarter of 2026, revealing significant losses. The company experienced a GAAP loss of $29.5 million and a non-GAAP loss of $16.2 million. Adjusted EBITDA also showed a loss of $17.1 million, highlighting ongoing financial difficulties.

Market Sentiment Analysis

CONCERNS & RISKS

  • The company reported a GAAP loss of $29.5 million.
  • Non-GAAP loss was $16.2 million, indicating financial struggles.
  • Adjusted EBITDA loss of $17.1 million reflects ongoing operational challenges.

Full Press Release Details

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Results: Revenue of $85.4 million GAAP loss of $29.5 million, or $(1.05) per share Non-GAAP loss of $16.2 million, or $(0.58) per share Adjusted EBITDA loss of $17.1 million Non

Frequently Asked Questions

What were Fulgent's Q2 2026 revenues?

Fulgent reported revenues of $85.4 million for the second quarter of 2026.

What was Fulgent's GAAP loss in Q2 2026?

The GAAP loss for Fulgent in Q2 2026 was $29.5 million.

How did Fulgent perform in terms of adjusted EBITDA?

Fulgent reported an adjusted EBITDA loss of $17.1 million in Q2 2026.

What was the non-GAAP loss for Fulgent in Q2 2026?

The non-GAAP loss for Fulgent in Q2 2026 was $16.2 million.

ShareAdd on Google
Tags: FLGT Viatris Investor Conferences Healthcare Fulgent Genetics financial results Q2 2026 GAAP loss
Last updated: Jul 30, 2026

Biotech snapshot

Cash runway
$276M liquidity · $0M/mo burn
Low dilution risk